U.S. Markets open in 8 hrs 14 mins
  • S&P Futures

    4,106.75
    -12.75 (-0.31%)
     
  • Dow Futures

    33,575.00
    -107.00 (-0.32%)
     
  • Nasdaq Futures

    13,784.00
    -45.50 (-0.33%)
     
  • Russell 2000 Futures

    2,228.10
    -11.10 (-0.50%)
     
  • Crude Oil

    59.32
    0.00 (0.00%)
     
  • Gold

    1,737.80
    -7.00 (-0.40%)
     
  • Silver

    25.15
    -0.18 (-0.69%)
     
  • EUR/USD

    1.1892
    -0.0013 (-0.1070%)
     
  • 10-Yr Bond

    1.6660
    0.0000 (0.00%)
     
  • Vix

    16.69
    -0.47 (-2.74%)
     
  • GBP/USD

    1.3670
    -0.0036 (-0.2597%)
     
  • USD/JPY

    109.5600
    -0.0900 (-0.0821%)
     
  • BTC-USD

    60,229.93
    -86.97 (-0.14%)
     
  • CMC Crypto 200

    1,289.06
    +98.37 (+8.26%)
     
  • FTSE 100

    6,915.75
    +30.43 (+0.44%)
     
  • Nikkei 225

    29,556.11
    -211.95 (-0.71%)
     

Epizyme: Q4 Earnings Insights

  • Oops!
    Something went wrong.
    Please try again later.
Benzinga Insights
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.

 

Shares of Epizyme (NASDAQ:EPZM) rose 3.4% in pre-market trading after the company reported Q4 results.

Quarterly Results

Earnings per share decreased 10.17% over the past year to ($0.65), which missed the estimate of ($0.58).

Revenue of $8,375,000 higher by 95.04% year over year, which beat the estimate of $6,190,000.

Outlook

Epizyme hasn't issued any earnings guidance for the time being.

Epizyme hasn't issued any revenue guidance for the time being.

Conference Call Details

Date: Feb 23, 2021

View more earnings on EPZM

Time: 08:00 AM

ET Webcast URL: https://edge.media-server.com/mmc/p/mgvnzo35

Price Action

52-week high: $25.49

52-week low: $9.90

Price action over last quarter: down 3.49%

Company Overview

Epizyme Inc is a clinical-stage biopharmaceutical company that is committed to rewriting treatment for cancer and other serious diseases through discovering, developing & commercializing novel epigenetic medicines. Its product candidates include tazemetostat, an inhibitor of the EZH2, which is in Phase II clinical trial for patients with relapsed or refractory non-hodgkin lymphoma (NHL), Phase II clinical trial for relapsed or refractory patients with mesothelioma, Phase I dose-escalation and expansion study for children with INI1-negative solid tumors. The company is also developing additional programs, such as pinometostat, an intravenously administered small molecule inhibitor of DOT1L for the treatment of acute leukemias & PRMT5 inhibitor.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.